Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
A nanoparticle that binds to immune cells in the body has been shown to tune down inflammation and offer a potential first-of-a-kind treatment for sepsis.
The Bill & Melinda Gates Foundation’s PATH Malaria Vaccine Initiative (MVI) has selected CMC Biologics for process development and manufacture of specific monoclonal antibodies (mAbs) to test for their capacity to protect humans from malaria infection.
Catalent has licensed an expression technology from Excelimmune it says could offer biologics makers a cost-effective and simple way to make antibody combination therapies.
Mice engineered to recognise light-emitting markers as self will let cancer drug developers to track tumor growth in animals with functioning immune systems say US researchers.
Intertek will open an immunochemistry lab in Manchester, UK to cater for growing demand for specialised analytical services from biologics and biosimilars developers.
Hospira has recalled one lot of the anaesthetic Bupivacaine after a customer discovered orange and black particles floating and embedded in a glass vial.
AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
A type 1 diabetes vaccine will enter human trials this year according to the leader of the UK research team developing a preventative therapy for the autoimmune disorder.
Abenza subsidiary Antitope has extended its relationship and will provide manufacturing cell lines for two developing HIV vaccines from the French National Institute of Health and Medical Research (INSERM); the National Health Agency for Research on AIDS...
German CRO Evotec AG and Padlock Therapeutics have successfully completed an initial goal in developing inhibitors of protein-arginine deiminases (PADs) and have further extended their collaboration through March 2017.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.
Manufacturers developing Ebola vaccines will be immune from lawsuits following a decision by US HHS (Health and Human Services) to issue a declaration on the matter.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
Lack of funding is threatening development of a nasal spray vaccine shown to provide long-term protection for non-human primates against the Ebola virus, the lead researcher told this publication in an exclusive interview.
The head of the US National Institutes of Health has said the organisation would have developed a finished Ebola vaccine by now if its funding had not been slashed over the last decade.
A candidate Ebola vaccine that uses Immunovaccine's formulation technology has stopped cynomolgus monkeys from catching the disease in a preclinical study.
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs.
An expression system developed by Cevec Pharmaceuticals has achieved 'very high' titres and bypassed problems that beset other platforms, moving the possibility of a commercial respiratory syncytial virus (RSV) one step closer.
CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
Kiadis Pharma has called on the German Red Cross to make its candidate cancer treatment ahead of contractors with less experience of manufacturing blood-derived products.
A consortium of European vaccine experts, including the Swiss CRO Preclin Biosystems, has received almost €5.5m ($7.1m) from the EU to develop a vaccine against the deadly MRSA bacteria.
GSK has ‘paused’ a Phase I trial of an MS drug and fired its China R&D chief, Jingwu Zhang, after finding 'manipulated' data in a paper published in Nature Medicine in 2010.
Scientists at the UK University have developed what they refer to as 'a simple lab-based skin test' which eliminates the risk of adverse reactions to new drugs, cosmetics, and household chemicals.
Profectus BioSciences has signed up San Diego-based CMO Althea Technologies to manufacture DNA vaccines after its deal with Boehringer Ingelheim ended due to currency issues.
CMO ProBioGen says its GlymaxX ADCC antibody enhancement technology can be adapted to any biomanufacturing cell line and will attract both Big and Small Pharma.
EpiVax says combining its immune 'off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.
